<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162653</url>
  </required_header>
  <id_info>
    <org_study_id>ALBINO</org_study_id>
    <nct_id>NCT03162653</nct_id>
  </id_info>
  <brief_title>Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome</brief_title>
  <acronym>ALBINO</acronym>
  <official_title>Effect of ALlopurinol in Addition to Hypothermia for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a Blinded Randomized Placebo-controlled Parallel Group Multicenter Trial for Superiority (Phase III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade do Porto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Udine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsingin Ja Uudenmaan Sairaanhoitopiirin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACE Pharmaceuticals BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term&#xD;
      disability in infants born at term in the western world, affecting about 1-4 per 1.000 life&#xD;
      births and consequently about 5-20.000 infants per year in Europe.&#xD;
&#xD;
      Hypothermic treatment became the only established therapy to improve outcome after perinatal&#xD;
      hypoxic-ischemic insults. Despite hypothermia and neonatal intensive care, 45-50% of affected&#xD;
      children die or suffer from long-term neurodevelopmental impairment. Additional&#xD;
      neuroprotective interventions, beside hypothermia, are warranted to further improve their&#xD;
      outcome.&#xD;
&#xD;
      Allopurinol is a xanthine oxidase inhibitor and reduces the production of oxygen radicals and&#xD;
      brain damage in experimental, animal, and early human studies of ischemia and reperfusion.&#xD;
&#xD;
      This project aims to evaluate the efficacy and safety of allopurinol administered immediately&#xD;
      after birth to near-term infants with HIE in addition to hypothermic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2018</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment</measure>
    <time_frame>at the age of 24 months</time_frame>
    <description>Where severe neurodevelopmental impairment is defined as any of the following: cognitive or language delay defined as a cognitive-composite-score or a language-composite-score on the Bayley Scales of Infant and Toddler Development (3rd edition) &lt; 85 and/or cerebral palsy (CP) according to SCPE criteria [SCPE Dev Med Child Neurol 2000].&#xD;
Primary endpoint will be analyzed in the two treatment groups by chi-square omnibus test with three possible exclusive outcomes (healthy, death, composite outcome for impairment) and post-hoc testing in case of revealing a p-value &lt; 0.05 within the omnibus test [Engel and Franz IJSMR 2016].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death or neurodevelopmental impairment (NDI)</measure>
    <time_frame>at 24months</time_frame>
    <description>survival without NDI versus Death or language-composite-score &lt; 85 or cognitive-composite-score &lt;85 or cerebral palsy - analysed by Cochrane-Mantel-Haenzel- X²-Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CP</measure>
    <time_frame>at 24 months</time_frame>
    <description>Incidence of CP according to SCPE criteria [SCPE Dev Med Child Neurol 2000]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFCS-score</measure>
    <time_frame>at 24 months</time_frame>
    <description>GMFCS-Score for quantification of the effects of cerebral palsy and other motor impairments (adapted from Palisano et al. [Palisano Med Child Neurol 1997]) using the ALBINO-GMFCS-score sheet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor-Composite-Score (Bayley III)</measure>
    <time_frame>at 24 months</time_frame>
    <description>The numerical data of the motor-composite-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor-Composite-Score dichotomised (Bayley III)</measure>
    <time_frame>at 24 months</time_frame>
    <description>The motor-composite-score will be dichotomised at the cut-off &lt;85 versus ≥85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive-Composite-Score (cognitive subscale, Bayley III)</measure>
    <time_frame>at 24 months</time_frame>
    <description>The numerical data of the cognitive-composite-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive-Composite-Score dichotomised (cognitive subscale, Bayley III)</measure>
    <time_frame>at 24 months</time_frame>
    <description>The cognitive-composite-score will be dichotomised at the cut-off &lt;85 versus ≥85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Language-Composite-Score (language subscale, Bayley III)</measure>
    <time_frame>at 24 months</time_frame>
    <description>The raw numerical data of the language-composite-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Language-Composite-Score dichotomised (language subscale, Bayley III)</measure>
    <time_frame>at 24 months</time_frame>
    <description>The language-composite-score will be dichotomised at the cut-off &lt;85 versus ≥85</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">846</enrollment>
  <condition>Encephalopathy, Hypoxic-Ischemic</condition>
  <condition>Infant, Newborn, Diseases</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Term and near-term infants with a history of disturbed labour who meet at least one&#xD;
        criterion of perinatal acidosis (or ongoing resuscitation) and at least two early clinical&#xD;
        signs of potentially evolving encephalopathy as defined herein:&#xD;
&#xD;
        Severe perinatal metabolic acidosis or ongoing cardiopulmonary resuscitation at 5 min after&#xD;
        birth:&#xD;
&#xD;
        At least 1 out of the following 5 criteria must be met&#xD;
&#xD;
          -  Umbilical (or arterial or reliable venous) blood gas within 30 min after birth with&#xD;
             pH&lt;7.0&#xD;
&#xD;
          -  Umbilical (or arterial or reliable venous) blood gas within 30 min after birth with&#xD;
             base deficit ≥16 mmol/l&#xD;
&#xD;
          -  Need for ongoing cardiac massage at/beyond 5 min postnatally&#xD;
&#xD;
          -  Need for adrenalin administration during resuscitation&#xD;
&#xD;
          -  APGAR score ≤5 at 10min AND&#xD;
&#xD;
        Early clinical signs of potentially evolving encephalopathy:&#xD;
&#xD;
        At least 2 out of the following 4 criteria must be met:&#xD;
&#xD;
          -  Altered state of consciousness (reduced or absent response to stimulation or&#xD;
             hyperexcitability)&#xD;
&#xD;
          -  Severe muscular hypotonia or hypertonia,&#xD;
&#xD;
          -  Absent or insufficient spontaneous respiration (e.g., gasping only) with need for&#xD;
             respiratory support at 10 min postnatally&#xD;
&#xD;
          -  Abnormal primitive reflexes (absent suck or gag or corneal or Moro reflex) or abnormal&#xD;
             movements (e.g., potential clinical correlates of seizure activity)&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  gestational age below 36 weeks&#xD;
&#xD;
          -  birth weight below 2500 g&#xD;
&#xD;
          -  postnatal age &gt;30min at the end of screening phase&#xD;
&#xD;
          -  severe congenital malformation or syndrome requiring neonatal surgery or affecting&#xD;
             long-term outcome&#xD;
&#xD;
          -  patient considered &quot;moribund&quot; / &quot;non-viable&quot; (e.g., lack of spontaneous cardiac&#xD;
             activity and ongoing chest compression at 30min)&#xD;
&#xD;
          -  decision for &quot;comfort care only&quot; before study drug administration&#xD;
&#xD;
          -  parents declined study participation as response to measures of community engagement&#xD;
&#xD;
          -  both parents are insufficiently fluent in the study site's national language(s) or&#xD;
             English or do not seem to have the intellectual capacity to understand the study&#xD;
             procedures and to give consent as judged by the personnel who had been in contact with&#xD;
             the mother/father before delivery.&#xD;
&#xD;
          -  both parents/guardians less than 18 years of age, in case of single parent/guardian&#xD;
             this one less than 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Minutes</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Franz, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Children's Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rüdiger Mario, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oldershausen Gabriele</last_name>
    <phone>+49 7071 29-86176</phone>
    <email>Albino@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Klebermaß-Schrehof, Assoz. Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel Allegaert, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Gunnar Naulaers, Prof. Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tartu Ulikool</name>
      <address>
        <city>Tartu</city>
        <zip>50090</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Poláčková, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjo Metsäranta, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel R Franz, MD</last_name>
      <phone>+49707129</phone>
      <phone_ext>0</phone_ext>
      <email>albino@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Gabriele von Oldershausen</last_name>
      <phone>+49707129</phone>
      <phone_ext>0</phone_ext>
      <email>albino@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Axel R Franz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Maiwald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Arand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella Mauro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon Benders, Prof. MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus Hf</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Stiris, Prof. MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersytet Medyczny Im Karola Marcinkowskiego W Poznaniu</name>
      <address>
        <city>Poznań</city>
        <zip>61701</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidade Do Porto</name>
      <address>
        <city>Porto</city>
        <zip>4099 002</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hercilia Guimarães, Prof. MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Para La Investigacion Del Hospital UniversitarioLa Fe De La Comunidad Valenciana</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximo Vento, Prof. MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaet Zuerich</name>
      <address>
        <city>Zuerich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Bassler, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.albino-study.eu</url>
    <description>official study homepage</description>
  </link>
  <reference>
    <citation>Maiwald CA, Annink KV, Rüdiger M, Benders MJNL, van Bel F, Allegaert K, Naulaers G, Bassler D, Klebermaß-Schrehof K, Vento M, Guimarães H, Stiris T, Cattarossi L, Metsäranta M, Vanhatalo S, Mazela J, Metsvaht T, Jacobs Y, Franz AR; ALBINO Study Group. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). BMC Pediatr. 2019 Jun 27;19(1):210. doi: 10.1186/s12887-019-1566-8.</citation>
    <PMID>31248390</PMID>
  </reference>
  <reference>
    <citation>Annink KV, Franz AR, Derks JB, Rudiger M, Bel FV, Benders MJNL. Allopurinol: Old Drug, New Indication in Neonates? Curr Pharm Des. 2017;23(38):5935-5942. doi: 10.2174/1381612823666170918123307. Review.</citation>
    <PMID>28925896</PMID>
  </reference>
  <reference>
    <citation>Deferm N, Annink KV, Faelens R, Schroth M, Maiwald CA, Bakkali LE, van Bel F, Benders MJNL, van Weissenbruch MM, Hagen A, Smits A, Annaert P, Franz AR, Allegaert K; ALBINO Study Group. Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance. Clin Pharmacokinet. 2021 Jul;60(7):897-906. doi: 10.1007/s40262-021-00991-6. Epub 2021 Feb 21.</citation>
    <PMID>33611729</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allopurinol</keyword>
  <keyword>hypothermia therapy</keyword>
  <keyword>hypoxic-ischemic encephalopathy</keyword>
  <keyword>neonatal oxygen deficiency</keyword>
  <keyword>childbirth outcome</keyword>
  <keyword>perinatal asphyxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

